Progyny, Inc. (PGNY) Q3 2025 10-Q Quarterly Report
Filed: Nov 7, 2025Period ending Sep 30, 2025
Health Care
Services-Misc Health & Allied Services, NECSEC EDGAR Progyny, Inc. (PGNY) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 7, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Progyny, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • No newly added risk factors disclosed; risk section restates prior known risks without material update
- • Most materially updated risk: client contract renewal risk heightened by a large client non-renewal with transition ending June 30, 2025
- • Legal/compliance risk: income tax expense rose 45% YoY to $31.5M YTD, reflecting greater U.S. and foreign tax obligations and deferred tax asset realizability considerations
- • Operational/market risk: 9% revenue growth driven by client base expansion to 553 clients and 6.7M covered lives, but utilization rates slightly declined to 0.54% in Q3 2025
- • Financial risk: modest 6% cost of services increase driven by higher medical and pharmacy costs and incremental headcount, partially offset by a $0.3M stock-based comp decline
Get deeper insights on Progyny, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.